Heron Therapeutics, Inc. (0J4V.L)
USD 2.4
(0.42%)
USD 2.4
(0.42%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -103.79 Million USD | 45.83% |
| 2022 | -166.36 Million USD | 21.97% |
| 2021 | -213.4 Million USD | 5.37% |
| 2020 | -219.71 Million USD | -7.99% |
| 2019 | -208.65 Million USD | -14.38% |
| 2018 | -182.42 Million USD | 4.6% |
| 2017 | -193.02 Million USD | -18.03% |
| 2016 | -169.81 Million USD | -68.43% |
| 2015 | -96.19 Million USD | -30.02% |
| 2014 | -73.98 Million USD | -36.69% |
| 2013 | -54.12 Million USD | -129.01% |
| 2012 | -23.63 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -4.1 Million USD | 54.37% |
| 2024 Q2 | -5.8 Million USD | -41.25% |
| 2023 Q1 | -32.34 Million USD | -65.33% |
| 2023 Q3 | -24.2 Million USD | 41.91% |
| 2023 Q4 | -9.5 Million USD | 60.73% |
| 2023 FY | - USD | 35.25% |
| 2023 Q2 | -41.66 Million USD | -28.81% |
| 2022 FY | - USD | 21.97% |
| 2022 Q3 | -41.17 Million USD | 15.67% |
| 2022 Q2 | -48.82 Million USD | 21.5% |
| 2022 Q1 | -62.2 Million USD | -21.62% |
| 2022 Q4 | -19.56 Million USD | 52.49% |
| 2021 Q4 | -51.14 Million USD | -0.37% |
| 2021 Q2 | -59.73 Million USD | -16.27% |
| 2021 Q3 | -50.95 Million USD | 14.7% |
| 2021 FY | - USD | 5.37% |
| 2021 Q1 | -51.37 Million USD | 6.56% |
| 2020 Q3 | -57.61 Million USD | -4.75% |
| 2020 Q4 | -54.98 Million USD | 4.57% |
| 2020 FY | - USD | -7.99% |
| 2020 Q1 | -52.11 Million USD | -3.4% |
| 2020 Q2 | -55 Million USD | -5.55% |
| 2019 Q1 | -64.23 Million USD | -32.18% |
| 2019 Q2 | -51.28 Million USD | 20.15% |
| 2019 Q4 | -50.39 Million USD | -46.8% |
| 2019 FY | - USD | -14.38% |
| 2019 Q3 | -34.33 Million USD | 33.06% |
| 2018 FY | - USD | 4.6% |
| 2018 Q4 | -48.59 Million USD | -17.38% |
| 2018 Q3 | -41.39 Million USD | -7.46% |
| 2018 Q2 | -38.52 Million USD | 25.36% |
| 2018 Q1 | -51.6 Million USD | 16.09% |
| 2017 FY | - USD | -18.03% |
| 2017 Q2 | -41.64 Million USD | 14.96% |
| 2017 Q3 | -40.9 Million USD | 1.76% |
| 2017 Q4 | -61.5 Million USD | -50.35% |
| 2017 Q1 | -48.97 Million USD | -15.5% |
| 2016 Q3 | -47.43 Million USD | -10.78% |
| 2016 FY | - USD | -68.43% |
| 2016 Q2 | -42.81 Million USD | -29.45% |
| 2016 Q1 | -33.07 Million USD | -7.3% |
| 2016 Q4 | -42.39 Million USD | 10.61% |
| 2015 FY | - USD | -30.02% |
| 2015 Q4 | -30.82 Million USD | -38.13% |
| 2015 Q1 | -20.2 Million USD | -4.67% |
| 2015 Q3 | -22.31 Million USD | 2.31% |
| 2015 Q2 | -22.84 Million USD | -13.04% |
| 2014 Q2 | -18.66 Million USD | -8.47% |
| 2014 Q3 | -18.8 Million USD | -0.73% |
| 2014 FY | - USD | -36.69% |
| 2014 Q1 | -17.2 Million USD | -25.29% |
| 2014 Q4 | -19.3 Million USD | -2.68% |
| 2013 FY | - USD | -129.01% |
| 2013 Q4 | -13.73 Million USD | -9.22% |
| 2013 Q1 | -12.68 Million USD | -47.84% |
| 2013 Q3 | -12.57 Million USD | 16.88% |
| 2013 Q2 | -15.13 Million USD | -19.3% |
| 2012 Q4 | -8.57 Million USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| uniQure N.V. | -253.1 Million USD | 58.992% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -105.236% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -17.966% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 69.956% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 60.98% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 11.779% |
| Imunon, Inc. | -20.78 Million USD | -399.426% |
| Dynavax Technologies Corporation | 9.66 Million USD | 1173.784% |
| Editas Medicine, Inc. | -163.11 Million USD | 36.37% |
| FibroGen, Inc. | -261.4 Million USD | 60.295% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 76.884% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -187.656% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 124.944% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 76.368% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 205.628% |
| Verastem, Inc. | -83.16 Million USD | -24.801% |
| Zoetis Inc. | 3.68 Billion USD | 102.817% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 102.254% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -18.718% |
| Homology Medicines, Inc. | -47.75 Million USD | -117.338% |
| Nektar Therapeutics | -243.1 Million USD | 57.306% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -2.941% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -178.39% |
| Perrigo Company plc | 646.2 Million USD | 116.062% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 30.855% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.08% |
| Illumina, Inc. | -608 Million USD | 82.929% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 100.961% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 103.188% |
| Waters Corporation | 1.02 Billion USD | 110.153% |
| Biogen Inc. | 2.37 Billion USD | 104.367% |
| Evolus, Inc. | -41.81 Million USD | -148.247% |
| Adicet Bio, Inc. | -136.53 Million USD | 23.981% |
| bluebird bio, Inc. | -167.16 Million USD | 37.909% |
| Geron Corporation | -174.78 Million USD | 40.616% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 54.501% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -12.721% |
| Myriad Genetics, Inc. | -67.8 Million USD | -53.086% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 79.501% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 108.916% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -133.573% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 133.451% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 102.23% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 106.189% |
| OPKO Health, Inc. | -65.51 Million USD | -58.422% |
| Exelixis, Inc. | 196.6 Million USD | 152.793% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 195.816% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -86.154% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 53.868% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 54.875% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 122.966% |
| Blueprint Medicines Corporation | -474.61 Million USD | 78.131% |
| Insmed Incorporated | -654.73 Million USD | 84.148% |
| TG Therapeutics, Inc. | 26.1 Million USD | 497.67% |
| Incyte Corporation | 919.42 Million USD | 111.289% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 79.459% |